 | Up a level |
Fuchs, Michael; Jacob, Anne Sophie; Kaul, Helen; Kobe, Carsten; Kuhnert, Georg; Pabst, Thomas; Greil, Richard; Bröckelmann, Paul J; Topp, Max S; Just, Marianne; Hertenstein, Bernd; Soekler, Martin; Vogelhuber, Martin; Zijlstra, Josée M; Keller, Ulrich Bernd; Krause, Stefan W; Dührsen, Ulrich; Meissner, Julia; Viardot, Andreas; Eich, Hans-Theodor; ... (2024). Follow-up of the GHSG HD16 trial of PET-guided treatment in early-stage favorable Hodgkin lymphoma. Leukemia, 38(1), pp. 160-167. Springer Nature 10.1038/s41375-023-02064-y
Borchmann, Peter; Plütschow, Annette; Kobe, Carsten; Greil, Richard; Meissner, Julia; Topp, Max S; Ostermann, Helmut; Dierlamm, Judith; Mohm, Johannes; Thiemer, Julia; Sökler, Martin; Kerkhoff, Andrea; Ahlborn, Miriam; Halbsguth, Teresa V; Martin, Sonja; Keller, Ulrich; Balabanov, Stefan; Pabst, Thomas; Vogelhuber, Martin; Hüttmann, Andreas; ... (2021). PET-guided omission of radiotherapy in early-stage unfavourable Hodgkin lymphoma (GHSG HD17): a multicentre, open-label, randomised, phase 3 trial. The lancet oncology, 22(2), pp. 223-234. Elsevier 10.1016/S1470-2045(20)30601-X
Mettler, Jasmin; Müller, Horst; Voltin, Conrad-Amadeus; Baues, Christian; Klaeser, Bernd; Moccia, Alden; Borchmann, Peter; Engert, Andreas; Kuhnert, Georg; Drzezga, Alexander; Dietlein, Markus; Kobe, Carsten (2019). Metabolic Tumor Volume for Response Prediction in Advanced-Stage Hodgkin Lymphoma. Journal of nuclear medicine, 60(2), pp. 207-211. Society of Nuclear Medicine 10.2967/jnumed.118.210047
Borchmann, Peter; Goergen, Helen; Kobe, Carsten; Lohri, Andreas; Greil, Richard; Eichenauer, Dennis A; Zijlstra, Josée M; Markova, Jana; Meissner, Julia; Feuring-Buske, Michaela; Hüttmann, Andreas; Dierlamm, Judith; Soekler, Martin; Beck, Hans-Joachim; Willenbacher, Wolfgang; Ludwig, Wolf-Dieter; Pabst Müller, Thomas Niklaus; Topp, Max S; Hitz, Felicitas; Bentz, Martin; ... (2018). PET-guided treatment in patients with advanced-stage Hodgkin's lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group. Lancet, 390(10114), pp. 2790-2802. Elsevier 10.1016/S0140-6736(17)32134-7
